Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis

Review (42 trials) reports ferric carboxymaltose induced significantly higher incidence of hypophosphataemia vs iron isomaltoside (47% vs. 4%), which did not resolve for at least 3 months in many patients. More severe iron deficiency & normal kidney function were risk factors.

Source:

British Journal of Clinical Pharmacology